Table 3.

Strongly encouraged, exploratory, and no longer recommended response measures for general chronic GVHD trials

Organ*	Strongly Encouraged	Exploratory	No longer recommended for general chronic GVHD studies
Skin		Clinician and patient reported skin and/or joint tightening	Body surface area of erythematous changes and moveable sclerosis Pigmentary changes
Eyes			Schirmer’s test
Mouth			Mucoceles, patient-reported mouth pain and dryness on a 0–10 scale
Upper GI	Weight
Lower GI	Weight
Liver			Aspartate aminotransferase
Lungs	Corrected DLCO, FVC, TLC, RV
Hematologic			Platelet count, absolute eosinophil count
Genitals		Female and male self-reported question: “Worse genital discomfort” on a 0–10 scale
Ancillary measures	SF-36v.2 (0–100) or FACT-BMT (0–148) in adults HAP (if the SF-36v2 is not used) (0–94) Patient overall severity score 0–10	PedsQL Clinician and patient-reported severity (0–10) and change (−3 to +3) for organ-specific chronic GVHD manifestations	Grip strength Children’s Health Rating Inventory Activity Scale for Kids

^*No measures for esophagus or joints and fascia

SF-36v2, Medical Outcome Study Short Form 36, version 2; FACT-BMT, Functional Assessment of Cancer Therapy-Bone Marrow Transplantation subscale; HAP, human activities profile; PedsQL, pediatric quality of life